20.66
+0.50
(2.48%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 20.07 - 20.75 |
| 52 week | 7.55 - 23.03 |
| Open | 20.30 |
| Vol / Avg. | 1.73M/1.78M |
| Mkt cap | 2.14B |
| P/E | - |
| Div/yield | - |
| EPS | -0.43 |
| Shares | 103.78M |
| Beta | 1.11 |
| Inst. own | 84% |
Events
Aug 7, 2013
Q2 2013 Isis Pharmaceuticals Earnings Release
Jun 25, 2013
Isis Pharmaceuticals Annual Shareholder Meeting
- 5:00PM EDT -
Jun 25, 2013
Isis' Annual Stockholder Meeting and Open House
- 5:00PM EDT -
May 30, 2013
Isis Pharmaceuticals at 38th Annual Deutsche Bank Health Care Conference
- 8:00AM EDT -
May 20, 2013
Isis Pharmaceuticals at UBS Global Healthcare Conference
- 9:00AM EDT -
May 15, 2013
Isis Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference -
May 7, 2013
Q1 2013 Isis Pharmaceuticals Earnings Conference Call -
May 5, 2013
2013 ARVO Annual Meeting
Apr 30, 2013
12th Annual Needham Healthcare Conference -
Apr 11, 2013
4th International Alpha-1 Patient Congress
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -3.86% | -64.16% |
| Operating margin | 3.75% | -72.21% |
| EBITD margin | - | 743.59% |
| Return on average assets | -1.22% | -12.71% |
| Return on average equity | -3.49% | -36.97% |
| Employees | 288 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma
Officers and directors
| Stanley T. Crooke M.D., Ph.D. | Chairman of the Board, President, Chief Executive Officer | |
| Elizabeth L. Hougen | Chief Financial Officer, Senior Vice President - Finance | |
| B. Lynne Parshall J.D. | Chief Operating Officer, Corporate Secretary, Director | |
| Patrick R. O'Neil Esq. | Senior Vice President - Legal, General Counsel | |
| C. Frank Bennett Ph.D. | Senior Vice President - Antisense Research | |
| Richard S. Geary Ph.D. | Senior Vice President - Development | |
| Brett P. Monia Ph.D. | Senior Vice President - Drug Discovery and Corporate Development | |
| Spencer R. Berthelsen M.D. | Independent Director | |
| Joseph Klein III | Independent Director | |
| Frederick T. Muto JD | Independent Director |